Evidence map›Paper›PMID 42205753›Full record

ReviewFrontiers in oncology2026

Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and

Yefei Ruan, Lin Qiu

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yefei RuanThe Affiliated Yangming Hospital of Ningbo University, Yuyao People's Hospital, Yuyao, China.
Lin QiuThe Affiliated Yangming Hospital of Ningbo University, Yuyao People's Hospital, Yuyao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the precision management of non-small cell lung cancer (NSCLC), identifying driver mutations and evaluating immune-related biomarkers are essential. Yet, clear therapeutic protocols remain absent for tumors that concurrently carry

Indexed as

MET14 exon skipping mutationnon-small cell lung cancerprogrammed death-ligand 1savolitinibtislelizumab

Identifiers

PMID42205753
PMCPMC13201154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.